The market expects Sage Therapeutics, Inc. (SAGE) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2023. This widely-known ...

Sage Therapeutics SAGE reported a loss of $3.37 per share for the third quarter of 2023, wider than the year-ago quarter’s loss of $2.31. The reported loss included restructuring expenses of $33.6 ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.80 per share a year ago. These ...

ATLANTA--(BUSINESS WIRE)--At the opening session of the 12 th annual New Cardiovascular Horizons (NCVH) meeting in New Orleans, Mary L. Yost, President of THE SAGE GROUP, spoke on the prevalence of ...

Sage Group PLC (SGPYY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

BEAUFORT, S.C.--(BUSINESS WIRE)--According to THE SAGE GROUP, in 2015 almost 20 million U.S. citizens suffered from PAD. Reflecting the aging population this number is projected to increase to 25 ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known consensus ...